Clinical Scorecard: Impact of 17-beta Estradiol-Dominant Gender-Affirming Hormone Therapy on Visceral Fat and Hepatic Lipids: Findings from a US Cohort Study

At a Glance

Key Highlights

• After 12 months of GAHT, visceral adipose tissue mass and volume did not change significantly.
• Intrahepatic triglyceride content decreased, indicating reduced hepatic fat.
• Appendicular lean body mass/height² decreased, suggesting increased risk of sarcopenia.

Guideline-Based Recommendations

Diagnosis

• Exclude individuals with pre-existing atherosclerotic cardiovascular disease, heart failure, or diabetes before GAHT initiation.
• Baseline and 12-month metabolic phenotyping including body composition, bone density, insulin sensitivity, and hepatic triglyceride measurement.

Management

• Administer GAHT consisting of 17β-estradiol combined with anti-androgen therapy (spironolactone, leuprolide, or bicalutamide) as prescribed by clinicians.
• Monitor and address potential decreases in lean body mass to mitigate sarcopenia risk.

Monitoring & Follow-up

• Assess visceral adipose tissue, bone density, insulin sensitivity, and hepatic triglyceride content at baseline and after 12 months of GAHT.
• Monitor systemic triglycerides, HDL, and LDL cholesterol levels periodically.
• Evaluate free testosterone levels as they independently predict changes in hepatic triglycerides.

Risks

• Potential decrease in lean body mass increasing sarcopenia risk.
• Increase in systemic triglyceride levels despite stable HDL and LDL cholesterol.
• Persistent cardiometabolic disease risk despite GAHT.

Patient & Prescribing Data

Transgender women and nonbinary individuals aged 16 years or older initiating estradiol and anti-androgen therapy without prior cardiovascular or diabetic conditions.

GAHT with estradiol and anti-androgens over 12 months does not alter visceral fat or insulin sensitivity but reduces hepatic fat and lean body mass, necessitating metabolic monitoring and risk mitigation strategies.

Clinical Best Practices

• Conduct comprehensive baseline metabolic assessments prior to GAHT initiation.
• Implement longitudinal monitoring of body composition and hepatic fat to detect adverse changes early.
• Develop strategies to mitigate sarcopenia risk, including possible interventions to preserve lean body mass.
• Consider free testosterone levels as a biomarker for hepatic fat changes during GAHT.
• Exclude patients with existing cardiovascular disease or diabetes from initial GAHT studies to isolate therapy effects.

References

• ClinicalTrials.gov NCT04128488